Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D B Johnson

Showing results (91-100 of 99) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 99 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanomaM H Pollack, A Betof, H Dearden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1987
Prolongation of survival for high-grade malignant gliomas with adjuvant high-dose BCNU and autologous bone marrow transplantationD B Johnson, J M Thompson, J A Corwin, et al.
Journal of the American College of Cardiology|January 1, 1997
Angiotensin-converting enzyme inhibitor therapy affects left ventricular mass in patients with ejection fraction > 40% after acute myocardial infarctionD B Johnson, R E Foster, F Barilla, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2016
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumabA M Menzies, D B Johnson, S Ramanujam, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 11, 2020
Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy<sup>☆</sup>C N Owen, A N Shoushtari, D Chauhan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 2, 2021
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanomaC N Owen, X Bai, T Quah, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 18, 2022
Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort studyF Dimitriou, K Namikawa, I L M Reijers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 9, 2025
Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanomaP Grover, S N Lo, I Li, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 22, 2021
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer ConsortiumP Grivas, A R Khaki, T M Wise-Draper, et al.
Pageof 10

Showing results (91-100 of 99) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 99 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanomaM H Pollack, A Betof, H Dearden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1987
Prolongation of survival for high-grade malignant gliomas with adjuvant high-dose BCNU and autologous bone marrow transplantationD B Johnson, J M Thompson, J A Corwin, et al.
Journal of the American College of Cardiology|January 1, 1997
Angiotensin-converting enzyme inhibitor therapy affects left ventricular mass in patients with ejection fraction > 40% after acute myocardial infarctionD B Johnson, R E Foster, F Barilla, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2016
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumabA M Menzies, D B Johnson, S Ramanujam, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 11, 2020
Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy<sup>☆</sup>C N Owen, A N Shoushtari, D Chauhan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 2, 2021
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanomaC N Owen, X Bai, T Quah, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 18, 2022
Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort studyF Dimitriou, K Namikawa, I L M Reijers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 9, 2025
Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanomaP Grover, S N Lo, I Li, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 22, 2021
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer ConsortiumP Grivas, A R Khaki, T M Wise-Draper, et al.
Pageof 10